Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare

JAMA Internal Medicine

Volumn 176, Issue 12, 2016, Pages 1818-1825

  Wang, Cunlin ^a   Kane, Robert ^a   Levenson, Mark ^a   Kelman, Jeffrey ^b   Wernecke, Michael ^c   Lee, Joo Yeon ^a   Kozlowski, Steven ^a   Dekmezian, Carmen ^c   Zhang, Zhiwei ^a   Thompson, Aliza ^a   Smith, Kimberly ^a   Wu, Yu Te ^a   Wei, Yuqin ^c   Chillarige, Yoganand ^c   Ryan, Qin ^a   Worrall, Chris ^b   MaCurdy, Thomas E ^c   Graham, David J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Centers for Medicare and Medicaid Services   (United States)

^c Acumen LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DRUG LABELING; ERYTHROCYTE TRANSFUSION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; PATIENT CARE; POLICY; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK REDUCTION; UNITED STATES; VENOUS THROMBOEMBOLISM; BLACK PERSON; BLOOD TRANSFUSION; CAUCASIAN; ECONOMICS; GOVERNMENT; HEALTH CARE POLICY; KIDNEY FAILURE, CHRONIC; MEDICAL FEE; MYOCARDIAL INFARCTION; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COHORT STUDIES; DRUG LABELING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH CARE REFORM; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MYOCARDIAL INFARCTION; REIMBURSEMENT MECHANISMS; REIMBURSEMENT, INCENTIVE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STROKE; UNITED STATES;

EID: 85011277763     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.6520     Document Type: Article

References (26)

1. United States Renal Data System. 2014 USRDS Annual Data Report: Epidemiology Of Kidney Disease in the United States. https://www.usrds.org/2014/view/Default.aspx. Accessed September 15, 2016.
2. Charytan C. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. Clin J AmSoc Nephrol. 2010;5(12):2355-2362.
3. Wish JB. Anemia management under a bundled payment policy for dialysis: A preview for the United States from Japan. Kidney Int. 2011;79(3): 265-267.
4. Solomon SD, Uno H, Lewis EF, et al; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146-1155.
5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590.
6. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-2098.
7. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82(2): 235-241.
8. Label FDA. Epogen (epoetin alfa). http://www .accessdata.fda.gov/drugsatfda-docs/label/2011/103234Orig1s5166-103234Orig1s5266lbl.pdf.
9. Brunelli SM, Monda KL, Burkart JM, et al. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis. 2013;61 (6):947-956.
10. Slinin Y, Ishani A. Dialysis bundling and small dialysis organizations: A call for close monitoring. Am J Kidney Dis. 2013;61(6):858-860.
11. Iglehart JK. Bundled payment for ESRD-including ESAs in Medicare's dialysis package. N Engl J Med. 2011;364(7):593-595.
12. Hirth RA, Turenne MN, Wheeler JR, et al. The initial impact of Medicare's new prospective payment system for kidney dialysis. Am J Kidney Dis. 2013;62(4):662-669.
13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
14. Andersen PK, Gill RD. Cox's regression model for counting processes: A large sample study. Ann Stat. 1982;(4):1100-1120.
15. Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM. The DOPPS Practice Monitor for US dialysis care: trends through August 2011. Am J Kidney Dis. 2012;60(1):160-165.
16. Chertow GM, Liu J, Monda KL, et al. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J AmSoc Nephrol. 2016; ASN.2015111232.
17. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J AmSoc Nephrol. 2009;4(suppl 1):S5-S11.
18. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J AmSoc Nephrol. 2007;2(1):89-99.
19. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
20. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J AmSoc Nephrol. 2005;16(7):2180-2189.
21. Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int. 2011;80(6):663-669.
22. Turenne MN, Cope EL, Porenta S, et al. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? J AmSoc Nephrol. 2015;26(3): 754-764.
23. Hirth RA, Turenne MN, Wilk AS, et al. Blood transfusion practices in dialysis patients in a dynamic regulatory environment. Am J Kidney Dis. 2014;64(4):616-621.
24. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10(10):1814-1821.
25. Lacson E Jr, Rogus J, Teng M, Lazarus JM, Hakim RM. The association of race with erythropoietin dose in patients on long-term hemodialysis.AmJ Kidney Dis. 2008;52(6):1104-1114.
26. Centers for Medicare and Medicaid Services. ESRD Quality Incentive Program. https://www.cms .gov/medicare/quality-initiatives-patient-assessment-instruments/esrdqip/index.html. Accessed September 15, 2016.